Introduction
============

Endometrial cancer is the sixth most common cancer diagnosed among women with approximately 320,000 new cases and 76,000 deaths worldwide each year ([@B20]). Early detection is common as the disease is symptomatic even at an early stage and therefore is often diagnosed at Stage I ([@B48]). Despite the fact that most cases are diagnosed early, the incidence and mortality rates for endometrial cancer have been rising in both developed as well as developing countries and are expected to rise further with the increasing aging population and high prevalence of obesity ([@B19]; [@B48]). Furthermore, although endometrial cancer is generally thought to be a cancer of the postmenopausal women, 14% of cases are diagnosed during premenopausal period with 5% of the patients younger than 40-year old ([@B15]).

In the past three decades, endometrial cancer has been broadly divided into two subtypes based on histological characteristics, expression of estrogen receptor (ER) and grade ([@B7]). Majority of endometrial cancer which are designated as Type I endometrioid endometrial cancer (EEC) account for more than 75% of all cases ([@B9]), follow the estrogen-related pathway, and arise from hyperplastic endometrium background ([@B3]). Frequently diagnosed in premenopausal and young postmenopausal women, Type I EEC is often low grade and well-differentiated thus carrying a favorable outcome ([@B24]). The less common Type II non-endometrioid endometrial cancer (NEEC), which accounts for 10--20% of all cases, follows the estrogen unrelated pathway and arise in background of atrophic endometrium ([@B14]). This type has a poorer prognosis and usually presents at the advanced stage, especially in older postmenopausal women ([@B1]). NEEC is also associated with a high mortality, reduced survival rates, and tendency to recur. This dualistic categorization has been incorporated into clinical decision-making algorithms to define high-risk patients, yet its prognostic value remains limited because one-fifth of EEC (i.e., Type I) will eventually relapse, whereas half of NEEC (i.e., Type II) do not ([@B7]). Furthermore, 15--20% of EEC are high-grade lesions, and it is unclear where they fit into the dualistic model ([@B69]).

This dualistic model has also been supported by molecular studies where Type I EEC has been symbolized by frequent alterations in *PTEN*, *PIK3CA*, *KRAS*, *CTNNB1*, and *ARID1A* as well as defects in DNA mismatch repair (MMR) resulting in the microsatellite instability (MSI) phenotype ([@B51]). In contrast, mutations in *TP53* and *PP2R1*A as well as a high expression of oncogene *Her2/ERBB2* are the major genetic changes among Type II NEEC ([@B38]; [@B51]). However, this classification is controversial due to existence of a minority of endometrial cancer cases with overlapping clinical features, morphological and molecular characterization which represents a major obstacle to effective cancer treatment ([@B58]). For example, Type I EEC is not completely ER positive and loss of ER expression is correlated with aggressive behavior, high grade histology, and poor survival rate ([@B47]; [@B2]). In contrast to breast cancer, where the ER status (in addition to progesterone) is a pillar for its molecular and clinicopathological classification ([@B49]), a comprehensive view of the mutation spectrum between ER positive and ER negative in the same molecular subtype (i.e., endometrioid) has not been fully elucidated. Therefore, the aim of this study is to characterize somatic gene alterations in ER positive and ER negative EEC using targeted deep sequencing of 409 cancer-related genes.

Materials and Methods {#s1}
=====================

Clinical Specimen, DNA Extraction, and Quality Assessment
---------------------------------------------------------

Fresh frozen tissues of EECs (*n* = 19) were obtained after hysterectomy from the patients admitted to the Universiti Kebangsaan Malaysia Medical Centre (UKMMC). The cancers were classified according to the World Health Organization (WHO) classification of tumors of the female reproductive system ([@B53]). In addition, fresh frozen normal endometrium (*n* = 10) were obtained from patients surgically treated for non-malignant endometrial diseases. This study was approved by the Universiti Kebangsaan Malaysia Research Ethics Committee (UKM 1.5.3.5/244/AP-2012-011) and carried out in accordance with the approved guidelines. All patients provided written informed consent for their tissue samples to be used for research. Immunohistochemical staining for ER (antibody clone 1D5, DAKO, Carpinteria, CA, United States) and Hematoxylin and Eosin (H&E) staining was performed on the frozen sections and then reviewed by a pathologist. Immunohistochemical staining for ER was scored as positive if 1% or more of tumor nuclei were immunoreactive and negative if less than 1% of tumor cell nuclei were immunoreactive. Only cancer specimens containing more than 80% cancer cells and normal tissues with less than 20% necrosis were subjected to DNA isolation using the QIAamp^®^ DNA Mini Kit (Qiagen, Valencia, CA, United States) following the manufacturer's protocol.

Next-Generation Sequencing
--------------------------

The Ion Ampliseq^TM^ Comprehensive Cancer Panel V2 (Life Technologies, Guilford, CT, United States), which covers 409 oncogenes and tumor suppressor genes, was used for library preparation (**Supplementary Table [S1](#SM3){ref-type="supplementary-material"}**) according to manufacturer's instruction. The libraries were then normalized to 12--25 pM for template preparation on the Ion One Touch (Life Technologies, Guilford, CT, United States). The clonal amplification of the DNA libraries on the Ion Sphere Particles (ISPs) was carried out using emulsion PCR and the subsequent isolation of templated ISPs was performed using Ion OneTouch ES (Life Technologies, Guilford, CT, United States). Subsequently, next-generation sequencing (NGS) was performed on the Ion Torrent Personal Genome Machine (PGM^TM^) using 318^TM^ chip and Ion Torrent PGM Sequencing 200 kit V2 (Life Technologies, Guilford, CT, United States).

Bioinformatics Analyses
-----------------------

### Read Mapping and Variant Calling

Data from the sequencing runs were automatically transferred to the Torrent Server hosting the Torrent Suite Software v4.0.3. The readings were mapped to the reference genome (hg19) using the Torrent Mapping Alignment program (TMAP). Variant calling was generated using Torrent Variant Caller v 4.0 with low stringency settings (Life Technologies, Guilford, CT, United States).

### Variant Annotation and Prioritization

The functional effects of the variants were further annotated using ANNOVAR ([@B66]) with respect to gene regions and filter-based annotations. Prediction on protein impact of variants was performed using SIFT, PolyPhen2 HDIV, PolyPhen2 HVAR, LRT, MutationTaster, MutationAssessor, FATHMM, GERP++, PhyloP, and SiPhy databases that are available in ANNOVAR. We classified SNVs as pathogenic if they were observed to be deleterious by three or more than three SNV protein prediction algorithms.

To evaluate which mutations could be actionable and to prioritize for the true somatic mutations, several additional filtering steps were performed. Details on filtrations steps are illustrated in **Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**. The alignment of each candidate variant was manually inspected to check for sequencing artifacts and alignment errors using the Integrated Genomic Viewer (IGV) ([@B63]). Oncoprint diagram and lollipop plot were created using Oncoprinter and Mutation Mapper tools, respectively ([@B10]; [@B22]). The detected mutations were compared to those in available cancer databases from the COSMIC v82 ([@B21]), MyCancerGenome ([@B65]), and International Cancer Genome Consortium (ICGC) database ([@B70]). Cancer Genome Interpreter was used to classify driver mutation among the somatic alterations ([@B59]).

To identify relevant genes for further characterization, we prioritized the genes involved in endometrial cancer carcinogenesis using following strategies: (1) genes associated with EEC carcinogenesis and (2) genes relevant to ER signaling pathways \[based on Kyoto Encyclopedia of Genes and Genomic (KEGG) estrogen signaling pathway (hsa04915)\] ([@B35]).

### Sanger Sequencing for Validation

Identified variants were selected randomly for validation by Sanger sequencing. Primers for Sanger sequencing validation were designed using the IDT-DNA Primer Quest (Coralville, IA, United States). The PCR primers were described in **Supplementary Table [S2](#SM4){ref-type="supplementary-material"}**. PCR amplifications were performed using Applied Biosystem AmpliTaq^®^ Gold 360 master Mix (Applied Biosystems, Foster City, CA, United States) following manufacturer's instructions. Sanger sequencing was performed using BigDye Terminator v.3.1 Cycle Sequencing kits (Applied Biosystems, Foster City, CA, United States) on an ABI 3500 Genetic Analyzer platform (Life Technologies, Guilford, CT, United States).

### Site-Directed Mutagenesis and Constructs

The wild-type plasmid construct of *WHSC1* (RC212404) was obtained from OriGene Technologies (Rockville, MD, United States). Site-directed mutagenesis was performed using the Quick-Change^TM^ Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, United States), according to the manufacturer's instructions. The mutagenic primers were designed using QuickChange Primer Design Program and the sequences were provided in **Supplementary Table [S3](#SM5){ref-type="supplementary-material"}**.

### Cell Lines and Transient Transfection

Endometrioid endometrial cancer-1 (ATCC^®^ CRL-2923^TM^) and 293T (ATCC^®^ CRL-3216^TM^) cells were maintained in RPMI 1640 and DMEM: F12 (both from Gibco, United States) supplemented with heat inactivated 10% fetal bovine serum (FBS; Gibco, United States). Twenty-four hours prior to transfection, cells were seeded in a 6-well plate with a density of 4 × 10^5^ (EEC-1) and 6 × 10^5^ (293T). Four micrograms of each construct was transfected using 8 μl Lipofectamine 2000 (Invitrogen, Carlsbad, CA, United States) according to the manufacturer's instructions. Control cells were cells transfected with the empty vector pCMV6.

### Gene Expression and Protein Analysis

Total RNA was isolated from the cell lines using the RNeasy Kit (Qiagen, Valencia, CA, United States) according to the manufacturer's directions and cDNA was synthesized using High Capacity RNA to cDNA Kit (Applied Biosystem, Foster City, CA, United States). Quantitative real-time PCR was performed using TaqMan Fast Advanced Master Mix on the ABI 7500 Fast Real-Time PCR system (Applied Biosystem, Foster City, CA, United States). Relative expression was calculated using the ΔΔC~t~ method ([@B44]) with GAPDH as the housekeeping gene.

Protein lysate was resolved on a mini-protean TGX precast gel of 4--20% polyacrylamide (BioRad Laboratories, Hercules, CA, United States) and analyzed against the following primary antibodies; anti-DDK (Clone OTI4C5) (OriGene Technologies, Rockville, MD, United States), NSD2 (G12), ERα (HC-20), and anti-β-actin (sc-47778) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, United States).

### Cell-Based Assays

Cell viability was assessed using PrestoBlue^®^ cell viability reagent (Invitrogen, Carlsbad, CA, United States), wound healing assay was performed using IBIDI Culture-Inserts (IBIDI GmbH, Martinsried, Germany), migration ability of the cells was assessed using QCM^TM^ 24-well cell migration assay (Millipore, Billerica, MA, United States), and colony formation assay was performed by seeding 500 transfected cells in six-well plates followed by incubation at 37°C for 14 days and crystal violet staining. All assays were performed in triplicate.

### BrdU Proliferation Assay

Endometrioid endometrial cancer-1 cell lines were seeded at 2 × 10^4^ cells per well in 96-well plate and transfected with mutants or wild type of WHSC1 expression constructs before BrdU incorporation using BrdU Cell Proliferation Assay (Millipore, Temecula, CA, United States).

### Luciferase Assay

To substantiate the importance of *WHSC1* as a potential coactivator, dual luciferase assay was performed. We used Cignal ERE Reporter Assay kit from SABiosciences (Valencia, CA, United States). 293T cells were plated at a density of 3 × 10^5^ cells per well (96-well plates) in phenol red-free DMEM: F12 with 10% v/v charcoal--dextran-treated FBS. The cells were then transfected with 100 ng of reporter plasmid, wild-type *WHSC1* plasmid, and Renilla. Each sample was done in triplicate. The *WHSC1* mutants were transfected in the same manner. After transfection for 24 h, the cells were stimulated with 10 nM E2 or vehicle (DMEM). The Dual-Glo Luciferase Assay System (Promega) was used according to the manufacturer's instructions using VARIOLUX luminometer. Values were normalized to Renilla luciferase activity.

Results
=======

Patient Demographic Data and Tumor Characteristic
-------------------------------------------------

Clinical specimens used in this study were collected from patients who were treated at the UKMMC. The information on the patient's age, degree of differentiation, FIGO staging of tumor, metastasis, and ER status is summarized in **Table [1](#T1){ref-type="table"}**. The majority of EEC in both groups were stage 1B 64% (7/11) in ER positive, 50% (4/8) in ER negative. While there are three cases of metastasis in ER negative = 37.5%, (3/8) has shown patients with advance disease.

###### 

Patient demographics and tumor characteristics.

  Characteristics             Classification   ER positive, *n* = 11   ER negative, *n* = 8
  --------------------------- ---------------- ----------------------- ----------------------
  **Age**                     **Average**      **52**                  **57**
  FIGO staging                IA               0 (0)                   0 (0)
                              IB               7 (64)                  4 (50)
                              IC               2 (18)                  2 (25)
                              IIA              1 (9)                   0 (0)
                              IIB              0 (0)                   1 (12.5)
                              IIIA             0 (0)                   0 (0)
                              IIIB             0 (0)                   1 (12.5)
                              N/A              1 (9)                   0 (0)
  Degree of differentiation   Grade 1          5 (45)                  4 (50)
                              Grade 2          4 (36)                  2 (25)
                              Grade 3          1 (9)                   1 (12.5)
                              N/A              1 (9)                   1 (12.5)
  Metastasis lymph nodes      Yes              0 (0)                   3 (37.5)
                              No               11 (100)                5 (62.5)

Mutations Analysis of Endometrial Cancer With Ion Ampliseq^TM^ Cancer Panel
---------------------------------------------------------------------------

All patients from both groups have at least three alterations among the 409 genes screened. A total of 741 variants were identified in 272 genes in ER positive subtype \[718 single-nucleotide variations (SNVs), 14 insertions/deletions (INDELs), and 9 block substitutions\] (**Figure [1A](#F1){ref-type="fig"}**). While in ER negative subtype, a total of 448 variants altered in 221 different genes, including 421 SNVs, 21 INDELs, and 6 block substitutions (**Figure [1B](#F1){ref-type="fig"}**). We noted that mutations distribution of EECs in both subtypes were genomically heterogeneous. There were five highly mutated patients (median 178 per tumor, range from 97 to 330) and another 14 patients were non-highly mutated (median 11 mutations per tumor; range 3--42). We further investigated and found that hypermutated phenotype group could have a perturbed DNA repair system due to frequently altered DNA repair genes especially in MMR genes such as (i.e., *MSH2*, *MSH6*, and *PMS1*) (**Supplementary Table [S4](#SM6){ref-type="supplementary-material"}**).

![**(A,B)** Bar charts showing the number of somatic alterations identified in each patients according to respective groups. Indel in these bar charts including frameshift and non-frameshift substitution. **(C)** Pie chart showing the frequency of functional impact of gene mutations based on protein prediction algorithms in ANNOVAR.](fphar-09-00750-g001){#F1}

Based on protein prediction algorithms among identified 1139 SNVs in both subtypes, 739 variants (65%) were predicted to have deleterious effects, 301 variants (27%) have possibly deleterious effects, while the other 78 variants (7%) has neutral or low protein impact (**Figure [1C](#F1){ref-type="fig"}**). We identified 134 out of 371 (36%) genes predicted as tumor driver which included a total of 295 alterations. From this 295 alteration, 178 (60%) were identified in ER positive whereby 9 out of 11 ER positive patients have at least two candidate driver alteration. Meanwhile in ER negative subtype, 117 (40%) alterations were identified in ER negative patients where all ER negative patients have at least three candidate driver alterations (**Supplementary Table [S5](#SM7){ref-type="supplementary-material"}**).

PTEN is the most frequently altered gene in ER positive subtype (64%, 7/11) while ARID1A is the most frequently altered gene in ER negative group (50%, 4/8) as shown in **Figure [2A](#F2){ref-type="fig"}** (**Supplementary Tables [S6](#SM8){ref-type="supplementary-material"}**, **[S7](#SM9){ref-type="supplementary-material"}**). Majority of *PTEN* alterations were missense and in-frame mutations. On the other hand, *ARID1A* mutations were truncating alterations including nonsense mutations and INDELs. Mutations in the ER signaling pathway is known to be important in endometrial cancer; therefore, we further examined the prevalence of mutations in the genes involved in ER signaling pathway. Overall, there are 38 genes out of 409 genes panel list of CCP known to be involved in ER signaling pathway (**Supplementary Table [S1](#SM3){ref-type="supplementary-material"}**). As shown in **Figure [2B](#F2){ref-type="fig"}** (**Supplementary Tables [S8](#SM10){ref-type="supplementary-material"}**, **[S9](#SM11){ref-type="supplementary-material"}**), ERBB3, GNAS, PIK3R1, and WHSC1 are the most frequently altered genes in ER positive subtype (36%, 4/11); (36%, 4/11); (27%, 3/11); and (27%, 3/11) while PIK3CA is the most frequently altered gene in ER negative group (50%, 4/8). **Table [2](#T2){ref-type="table"}** showed classification based on protein impact prediction and candidate driver mutations for each alteration in *PTEN*, *ARID1A*, *PIK3CA*, *ERBB3*, *GNAS*, *PIK3R1*, and *WHSC1*.

###### 

Classification of somatic alterations in PTEN, PIK3CA, ARID1A, ERBB3, GNAS, PIK3R1, and WHSC1 genes.

  Patient   ER subtype   Gene     Exonic function              Protein change   Exon   Protein impact prediction   Driver prediction
  --------- ------------ -------- ---------------------------- ---------------- ------ --------------------------- -------------------
  IT        ER + VE      PTEN     Nonframeshift substitution   R130P            5      NA                          Driver
  2T        ER + VE      PTEN     Nonframeshift substitution   R130G            5      NA                          Driver
  4T        ER + VE      PTEN     Nonsynonymous SNV            K128T            5      Deleterious                 Driver
  6T        ER + VE      PTEN     Frameshift deletion          R11fs            1      NA                          Driver
  26T       ER + VE      PTEN     Nonframeshift substitution   R130Q            5      NA                          Driver
  28T       ER + VE      PTEN     Nonsynonymous SNV            P190L            6      Deleterious                 Passenger
  29T       ER + VE      PTEN     Nonsynonymous SNV            F341V            8      Deleterious                 Driver
  29T       ER + VE      PTEN     Nonsynonymous SNV            D92E             5      Deleterious                 Driver
  7T        ER - VE      PTEN     Stopgain SNV                 S59X             3      Deleterious                 Driver
  7T        ER - VE      PTEN     Stopgain SNV                 E7X              1      NA                          Driver
  9T        ER - VE      PTEN     Nonsynonymous SNV            F145V            5      Deleterious                 Driver
  24T       ER - VE      PTEN     Nonsynonymous SNV            I122N            5      Deleterious                 Driver
  22T       ER + VE      PIK3CA   Nonsynonymous SNV            T1025A           21     Possibly deleterious        Driver
  22T       ER + VE      PIK3CA   Nonsynonymous SNV            P449T            8      Deleterious                 Driver
  29T       ER + VE      PIK3CA   Nonsynonymous SNV            E453K            8      Possibly deleterious        Driver
  29T       ER + VE      PIK3CA   Nonsynonymous SNV            E365K            6      Possibly deleterious        Driver
  7T        ER - VE      PIK3CA   Nonsynonymous SNV            E81K             2      Deleterious                 Driver
  7T        ER - VE      PIK3CA   Nonsynonymous SNV            Q879K            18     Possibly deleterious        Passenger
  7T        ER - VE      PIK3CA   Nonsynonymous SNV            I816T            17     Deleterious                 Passenger
  7T        ER - VE      PIK3CA   Nonsynonymous SNV            R54K             2      Possibly deleterious        Passenger
  9T        ER - VE      PIK3CA   Nonsynonymous SNV            G118D            3      Deleterious                 Driver
  11T       ER - VE      PIK3CA   Nonsynonymous SNV            Q60H             2      Possibly deleterious        Passenger
  27T       ER - VE      PIK3CA   Nonsynonymous SNV            M1043V           21     Deleterious                 Driver
  22T       ER + VE      ARID1A   Stopgain SNV                 S2269X           20     Deleterious                 Passenger
  26T       ER + VE      ARID1A   Stopgain SNV                 R1989X           20     Deleterious                 Driver
  26T       ER + VE      ARID1A   Nonsynonymous SNV            R1636W           18     Deleterious                 Driver
  29T       ER + VE      ARID1A   Nonsynonymous SNV            P1576L           18     Deleterious                 Passenger
  7T,9T     ER - VE      ARID1A   Stopgain SNV                 R1989X           20     Deleterious                 Driver
  7T        ER - VE      ARID1A   Nonsynonymous SNV            S1985P           20     Deleterious                 Passenger
  9T        ER - VE      ARID1A   Frameshift deletion          G2040fs          20     NA                          Driver
  11T       ER - VE      ARID1A   Frameshift deletion          G324fs           1      NA                          Driver
  27T       ER - VE      ARID1A   Stopgain SNV                 R1335X           16     Deleterious                 Driver
  2T        ER + VE      ERBB3    Nonsynonymous SNV            P558S            14     Deleterious                 Passenger
  2T        ER + VE      ERBB3    Nonsynonymous SNV            R488Q            12     Deleterious                 Passenger
  6T        ER + VE      ERBB3    Nonsynonymous SNV            L924V            23     Deleterious                 Driver
  26T       ER + VE      ERBB3    Nonsynonymous SNV            L143M            4      Deleterious                 Driver
  29T       ER + VE      ERBB3    Nonsynonymous SNV            G1073V           27     Possibly deleterious        Passenger
  29T       ER + VE      ERBB3    Nonsynonymous SNV            R670Q            17     Neutral/Benign              Passenger
  4T        ER - VE      ERBB3    Frameshift deletion          E560fs           14     NA                          Passenger
  6T        ER + VE      GNAS     Stopgain SNV                 S192X            1      Possibly deleterious        NA
  26T       ER + VE      GNAS     Stopgain SNV                 R327X            11     Possibly deleterious        Passenger
  29T       ER + VE      GNAS     Nonsynonymous SNV            I39T             1      Deleterious                 NA
  29T       ER + VE      GNAS     Nonsynonymous SNV            P338L            1      Neutral/benign              NA
  4T        ER + VE      GNAS     Nonsynonymous SNV            R194P            1      Neutral/benign              NA
  21T       ER + VE      PIK3R1   Nonframeshift deletion       578_580del       13     NA                          Passenger
  26T       ER + VE      PIK3R1   Nonsynonymous SNV            M525I            13     Possibly deleterious        Passenger
  29T       ER + VE      PIK3R1   Stopgain SNV                 R348X            9      Deleterious                 Driver
  29T       ER + VE      PIK3R1   Stopgain SNV                 R162X            4      Deleterious                 Driver
  11T       ER - VE      PIK3R1   Nonframeshift deletion       404_405del       10     NA                          Passenger
  22T       ER + VE      WHSC1    Nonsynonymous SNV            K547E            7      Deleterious                 Driver
  22T       ER + VE      WHSC1    Stopgain SNV                 R824X            13     Deleterious                 Passenger
  26T       ER + VE      WHSC1    Nonsynonymous SNV            R1126H           19     Deleterious                 Driver
  29T       ER + VE      WHSC1    Nonsynonymous SNV            L1268P           21     Deleterious                 Driver
  9T        ER - VE      WHSC1    Nonsynonymous SNV            P748L            12     Deleterious                 Driver

![Frequency of mutations in **(A)** genes related in carcinogenesis of EEC. *PTEN* is the most frequently altered gene in ER positive subtype (64%, *n* = 11); *ARID1A* is the most frequently altered gene in ER negative group (63%, *n* = 8). **(B)** Frequency of mutations in genes relevant to ER signaling pathway compiled from literatures. *ERBB3* and *GNAS* are the most frequently altered genes in ER positive subtype (36%, *n* = 11); PIK3CA is the most frequently altered gene in ER negative group (50%, *n* = 8).](fphar-09-00750-g002){#F2}

Mutations Distribution in the Functional Domains of *PTEN*, *ARID1A*, *ERBB3*, and *WHSC1*
------------------------------------------------------------------------------------------

Mutations distribution in the functional domains of *PTEN*, *ARID1A*, and *WHSC1* was illustrated in **Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}**. Mutations in *PTEN* were localized to the catalytic phosphatase domain, with majority of mutants belongs to ER positive subtype group including the recurrent hotspot R130 residue, D92E, K128T (**Supplementary Figure [S2a](#SM2){ref-type="supplementary-material"}**). In addition, a frameshift deletion (R11fs) and two missense mutations (P190L and F341V) in C2 domain were also found in ER positive subtype. While in ER negative subtype group, two nonsense mutations (E7X and S59X) and two missense alterations (I122N and F145V) located on phosphatase domain have been identified. Most of these mutations have been reported via COSMIC v82, with the exception to R11fs, which was identified in our study.

Out of the 19 EECs sequenced, seven patients had nine *ARID1A* mutations (four mutations were identified in ER positive and five in ER negative EEC patients). Interestingly, recurrent hotspot mutation (R1989X) was observed in both ER positive and ER negative subtype group as shown in **Supplementary Figure [S2b](#SM2){ref-type="supplementary-material"}**. More *ARID1A* mutations were identified among ER negative subtype group, with mainly truncating type of mutations (nonsense and frameshift deletion) (G324fs, R1335X, R1989X, and G2040fs) and a missense mutation (S1985P). However, two nonsense mutations (R1989X and S2269X) and two missense mutations (P1576L and R1636W) which were located on non-functional domain of *ARID1A* have been identified in ER positive subtype. This study is the first to report the somatic G2040fs variant in EEC.

Higher mutation frequency of *ERBB3* was observed in ER positive subtype (36%, 4/11) compared to ER negative subtype (18%, 1/8). As shown in **Supplementary Figure [S2c](#SM2){ref-type="supplementary-material"}**, the missense mutations in ER positive sample were mapped at functional domain of ERBB3 gene including two in extracellular domain (L143M and P558S) and one in tyrosine kinase domain (L924V), while the others mapped on non-functional domain (R488Q), (R670Q), and (G1073V). Nevertheless, the single frameshift deletion mutation (E560fs) reported in ER negative subtype was located at the extracellular domain IV of *ERBB3*. To date, most of the mutations we discovered in ERBB3 gene are novel, except for L143M, R488Q, and R670Q that have been recorded in Cosmic v82 and ICGC database, respectively.

*WHSC1* was found to be altered in three ER positive patients and one ER negative patient. Majority of these somatic variations were distributed along the functional domain of *WHSC1* as shown in **Supplementary Figure [S2d](#SM2){ref-type="supplementary-material"}**. All of the variants identified in this study are novel, with the exception of a mutation on the catalytic SET domain (R1126H) that has been identified in several cancers (**Supplementary Table [S10](#SM12){ref-type="supplementary-material"}**). One missense mutation K547E was identified in an area without a defined domain, while two missense mutations (P748L and L1268P) were located within the plant homeodomain (PHD) domains II and V, respectively. A nonsense mutation (R824X) was identified which was predicted to cause premature truncation of WHSC1 protein with a deletion of C terminal functional domains including PHD IV, proline--tryptophan--tryptophan--proline-2 (PWWP2), SET, and PHD V-CH5CH domain. The frequency and location of alterations in *WHSC1* suggest that these cancer-associated mutations may have functional consequences.

Expression Analysis of Wild-Type and Mutant Constructs
------------------------------------------------------

The level of *WHSC1* expression was firstly screened in several cell lines (**Figure [3A](#F3){ref-type="fig"}**) in order to gauge its expression. Upon transfection, *WHSC1* mRNA levels were significantly reduced in the transfected cells with the mutant constructs K547E, R824X, and R1126H compared to the wild type indicating that these mutations affected the stability of the mRNA levels. However, the wild type and mutant L1268P were equally expressed in the transfected EEC-1 cell line (**Figure [3B](#F3){ref-type="fig"}**). This result was confirmed by the Western blot in EEC-1 and 293T cell lines (**Figure [3C](#F3){ref-type="fig"}**). Of note however, there is a second migrating band seen in L1268P in Western blot assay, which might explain the differences of mRNA of transcription level of L1268P and other mutant constructs.

![WHSC1 gene and protein analysis. **(A)** Quantification of mRNA from nuclear extract of normal prostate cell lines RPWE1 and endometrial cancer cell lines (EEC-1, HTB-112, KLE). **(B)** Quantification of mRNA expression of mutant *WHSC1* in EEC-1 cell line. Relative WHSC1 mutants were calculated in comparison to WT *WHSC1* 48 h post-transfection by real-time PCR and normalized to GAPDH mRNA expression. Negative control (no template) was included in each experiment (mean ± SD, *n* = 2, ^∗^*p* \< 0.05). The mRNA expression of WT was assigned as 1. **(C)** Western blot analysis shows protein expression of wild type and *WHSC1* mutants in EEC-1 and 293T cell lines after 48 h post-transfection. Total protein harvested from EEC-1 cells and 293T cells solubilized in cell lysis buffer were analyzed using precast SDS 4--12% gels. The WT and mutants of WHSC1 (152.1 kDa) were detected using Anti-DDK Clone OTI4C5 (mouse origin). While β-actin (47 kDa) was detected using anti-β-actin (mouse origin) for positive control. Mutants *WHSC1* promote cell growth. **(D)** Mutants *WHSC1* promote cell viability. At 72 h, the mutants K547E, R1126H, and L1268P resulted in 15, 19, and 18% increase significantly in motility, respectively, over EV in EEC-1. Statistical significance in all cases was measured by Student's *t*-test (^∗^*p* \< 0.05), *n* = 3. Error bars represent average ± SD. Overall *p*-values were calculated by two-way ANOVA for time. **(E)** Mutants *WHSC1* promote cell proliferation. BrdU colorimetric incorporation assay shows that *wild type* of *WHSC1*, R1126H, and L1268P significantly increased cell proliferation in EEC-1. Statistical significance in all cases was measured by Student's *t*-test (^∗^*p* \< 0.05), *n* = 2. Error bars represent average ± SD.](fphar-09-00750-g003){#F3}

Assessment of Oncogenic Properties of *WHSC1* Mutants
-----------------------------------------------------

At 72 h, the mutants K547E, R1126H, and L1268P showed a 15 (*p* = 0.0002), 19 (*p* = 0.0043), and 18% (*p* = 0.0056) significant increase in cell proliferation, respectively, over the empty vector control in EEC-1 cell line (**Figure [3D](#F3){ref-type="fig"}**). The effect of the *WHSC1* mutants on cell proliferation was further assessed by quantifying the activity of proliferating cells within 24 h after BrdU labeling. BrdU incorporation assay revealed significant increase in DNA synthesis in *WHSC1* wild type (*p* = 0.0190), R1126H (*p* = 0.0341), and L1268P (*p* = 0.0136) mutants, relative to empty vector. In contrast, no significant effect on DNA synthesis was caused by the K547E and R824X mutants (**Figure [3E](#F3){ref-type="fig"}**).

To further address the role of constitutive activation of *WHSC1* mutants on cell migration, we employed both the wound-healing and transwell migration assays. As shown in **Figure [4A](#F4){ref-type="fig"}**, the open area was rapidly covered by the mutant R1126H and L1268P in comparison with control (*p* = 0.0049 and *p* = 0.0040, respectively). The quantified open area in vector control cells reduced from 100 to only 76%, while R1126H mutant cells reduced from 100 to 95%, whereas L1268P mutant caused reduction from 100 to 94%. The wild type *WHSC1* also showed significant wound closure from 100 to 85% (*p* = 0.0233). To further confirm migration ability of the mutants, we employed the transwell migration assay. Similarly, EEC-1 transfected with *WHSC1* mutants R1126H and L1268P displayed a significant increase in number of migrated cells (**Figure [4B](#F4){ref-type="fig"}**) (*p* = 0.0102 and *p* = 0.0086, respectively). In this transwell migration assay, the wild-type *WHSC1* also showed potential migration ability compared with vector alone control cells (*p* = 0.0233). In addition, only mutants R1126H and L1268P showed a significant increase in colony number compared to empty vector (**Figure [4C](#F4){ref-type="fig"}**) (*p* = 0.00416 and *p* = 0.0232, respectively).

![Effect of *WHSC1* mutants on cell migration and clonogenic potential. **(A)** Wound healing assay displayed significant increase in average rate of wound closure at 72 h shown in R1126H and L1268P compared with EV and WT. **(B)** Transwell migration assay showed the numbers of migrated mutants R1126H and L1268P were significantly higher than EV. **(C)** Clonogenic survival was assessed by colony formation assay at day 14. The numbers of colonies were counted after crystal violet staining, and are expressed as percentage of cells expressing empty vector. There is significance of colony formation in R1126H and L1268P when compared with empty vector. No obvious effects were observed on the colony formation ability of EEC-1 cells after transfection with WT and mutants K547E and R824X. Statistical significance was measured by Student's *t*-test (^∗^*p* \< 0.05), *n* = 3. Error bars represent average ± SD.](fphar-09-00750-g004){#F4}

*WHSC1* Regulates ERα Gene Expression
-------------------------------------

Both R1126H and L1268P led to a significant increase of the coactivation potential in *WHSC1* (**Figure [5](#F5){ref-type="fig"}**) albeit lower than the wild type *WHSC1* when compared with empty vector. However, the truncated R824X mutant showed reduction of the coactivation potential of *WHSC1* suggesting that the catalytic SET activity is required for its ability to stimulate estrogen-dependent gene transcription. When compared all mutants with the wild type, only L1268P signaling did not differ significantly.

![Effects of *WHSC1* mutations on transcriptional activation of Estrogen Receptor Gene (ERα). WT *WHSC1* showed increase in ERE-mediated luciferase activity relative to EV. K547E, R824X, and R1126H were associated with reduced ability to activate ER activity, compared to WT. Whereas L1268P activated ER activity comparable to WT (n.s.). Data are presented as mean values ± SD, *n* = 2.](fphar-09-00750-g005){#F5}

Activating *WHSC1* L1268P Is Sensitive to Fulvestrant
-----------------------------------------------------

Fulvestrant acts as an antagonist to inhibit ER activity; therefore, we examine the effect of *WHSC1* R1126H and L1268P on the dose-dependent inhibition of proliferation in EEC-1 cells. Fulvestrant was able to inhibit the activity of wild type and *WHSC1* mutants. As shown in **Figures [6A,B](#F6){ref-type="fig"}**, L1268H had significantly greater antiproliferative effect only when compared with the empty vector with a 60% growth inhibition (*p* = 0.0281) compared to the wild type (54%) which was not significant (*p* = 0.362). The estrogen responsiveness was assayed as shown in **Figure [6C](#F6){ref-type="fig"}**, where we compared the ability of Fulvestrant to reduce ER protein levels in wild-type and mutants *WHSC1*, in the presence and absence of estrogen. We observed that Fulvestrant was able to downregulate the ER proteins of both wild type and mutants, with more reduction seen in the L1268P mutant's ER proteins level. Upon treatment with estradiol and Fulvestrant, a clear reduction of steady-state L1268P *WHSC1* mutant's exogenous protein can be seen in the Western blot assay.

![Effect of Fulvestrant on cell proliferation in mutants *WHSC1* expressing EEC1 cells. **(A)** Treatment was performed with 10 nM E2 and various dosage of Fulvestrant for 24 h. **(B)** Quantification of proliferation after exposure to 10 nM E2 and 10^-3^ M Fulvestrant. The values represent the percentage of growing cells compared to the normalized control (100%). Results represent mean values ± SD, *n* = 2 performed in triplicate. *WHSC1* mutants counteract the effect of ER inhibitor. **(C)** EEC-1 cells were transiently transfected with WT, R1126H, and L1268P mutant constructs and treated with 10 nM E2 or 100 nM of Fulvestrant for 24 h. Protein lysates were prepared and analyzed by Western Blot with indicated antibodies.](fphar-09-00750-g006){#F6}

Discussion
==========

Over the past few years emergence of novel technologies based on NGS have led to a new paradigm in understanding the mutational landscape of endometrial cancers. However, most studies were limited to either characterization of endometrial cancer without stratification based on grade and histological subtypes, or were focused on aggressive serous carcinoma subtype of endometrial cancer only ([@B37]; [@B39]; [@B43]; [@B12]). Our study is not only the first report on the mutational landscape in ER positive and ER negative EEC, but also on the functional analysis of a potential gene candidate, *WHSC1*, involved in ER positive endometrioid tumorigenesis. Of the 11 ER positive and 8 ER negative EEC patients sequenced in our study, the mutation spectrum notably diverges among both subtypes.

Among known genes that have been reported to be altered in endometrial cancer in earlier studies, *PTEN* mutations occur frequently in ER positive subtype compared to ER negative subtype. In the TCGA study on EEC, *PTEN* mutations have also been associated with ER expression in endometrial cancer ([@B62]). However, our study showed that *PIK3CA* mutations were comparable between both ER subtypes with more events occurring in the ER negative subtype compared to ER positive subtype. This is inconsistent with results from TCGA on breast cancer, which suggested the association between *PIK3CA* with ER positive expression ([@B61]). From the 10 patients with *PTEN* mutation in our study, only 3 patients had mutation in *PIK3CA*, which is consistent with other investigators that claimed *PIK3CA* mutations are mutually exclusive with *PTEN* mutations, suggesting that carcinogenic signaling through phosphatidylinositol 3-kinase (PI3K) pathway is mediated either through inactivation of *PTEN* or activation of *PIK3CA* ([@B55]). *ARID1A* mutations were identified in both endometrial cancer subtypes but more commonly seen in the ER negative subtype. Almost all *ARID1A* mutants in our analysis coexist with *PTEN* and *PIK3CA* mutations, and it is postulated that these mutations together induce aberrant activation of PI3K and protein kinase B (AKT) phosphorylation that result in inhibition of cell survival and apoptosis ([@B43]).

PTEN is a 200-kb gene located on chromosome 10q23.3 that consists of nine exons coding for 403 amino acids yielding a 47 kDa protein ([@B40]). This tumor suppressor gene plays an important role in the tumorigenesis of endometrial cancer, particularly in EEC ([@B13]; [@B51]; [@B62]). *PTEN* functions primarily as a lipid phosphatase via a dual specificity protein phosphatase dualistic domain ([@B46]). Remarkably, most reported mutations (R130, I122N, K128T) are clustered within the phosphatase signature motif between codon 122--132 that has been considered as the mutation hotspot site ([@B54]; [@B3]). In addition, mutations on the phosphatase binding loop D92E on this domain play critical roles as well ([@B26]). These mutants may abolish the phosphatase activity of the substrate phosphoinositide lipid, a key signaling component of PI3K pathway that regulate cell growth, proliferation, migration, and apoptosis ([@B17]). In comparison, mutants located on C2 domain (P190L and F341V) could impair the phosphoinositide lipid binding function, ultimately its growth-suppressing activity despite retaining the catalytic phosphatase activity ([@B50]). Other truncating mutations including nonsense and frameshift deletion (E7X, S59X, and R11fs) may result in functional inactivation of PTEN protein function, which leads to tumorigenesis ([@B68]). A number of *PTEN* missense mutations have been screened for its phosphatase activity which is important for its tumor suppression function, and majority of the mutants were shown to eliminate or reduce phosphatase activity ([@B28]).

*ARID1A* mutations have been increasingly reported upon the emergence of NGS technology especially among various malignancies ([@B34]) including endometrial cancer ([@B43]). *ARID1A* is located on chromosome 1p36.11 and it contains 20 coding exons. The gene encodes a 24-kDa chromatin remodeling protein consisting of 2285 amino acids and a member of SWI/SNF family which plays a significant role in regulating the transcription of genes via ATP hydrolysis ([@B67]). Therefore, it is critical in regulating diverse cellular processes including DNA repair, differentiation, and development as well as tumor suppression ([@B45]). The *ARIDIA* mutations identified in our study are consistent with others regardless of the type of cancers, where most were truncating mutations that would result in loss of function, supporting its tumor suppressor role ([@B27]; [@B11]). Both nonsense and frameshift mutants (R1335X, R1989X, S2269X, G324fs, and G2040fs) would result in loss of function *ARID1A* protein by nonsense-mediated mRNA decay and degradation of misfolded truncated proteins. Thus, its tumor suppression activity is abolished due to disruption in CDKN1A and SMAD3 pathway which is related to cell cycle regulation and aberrant activation of PI3K/AKT pathway ([@B8]). Missense mutations occur less frequently in *ARID1A*; hence, the functional manifestations are poorly understood ([@B4]). Our study showed that the mutations commonly occurred in the ER negative subtype group, suggesting that inactivation of *ARID1A* might play important role in ER-mediated transcription in endometrial cancer. Moreover, the SWI/SNW complex has been reported to be vital for the transcriptional activation of ER ([@B5]). Mutation in *ARID1A* is not that frequent in breast cancer (only ∼5%) ([@B34]) and there has been no reported association with ER status. However, low *ARID1A* expression has been found to associate with ER negativity of breast cancer ([@B71]).

By focusing on genes involved in the ER signaling pathway, we identified relatively frequent mutations in *ERBB3*, *GNAS*, *PI3KR1*, and *WHSC1* in ER positive subtype. Previous data by TCGA reported that 5.2% (16/373) of EEC have *ERBB3* mutations ([@B10]). This gene is located on 12q13.2 chromosome, consists of 28 exons, and encodes a protein composed of 1342 amino acids ([@B57]). *ERBB3* encodes a member of EGFR family receptor tyrosine kinase, which is a well-known gene to be amplified and overexpressed in various cancers ([@B52]). With emergence of NGS, more somatic mutations in *ERBB3* have gained attention. ERBB3 has been uncovered as a driver cancer gene in endometrial cancer through whole exome sequencing and loss of function screening by [@B43]. Using whole exome sequencing, *ERBB3* mutations have been reported in colon, gastric, and gallbladder cancers ([@B32]; [@B41]). *ERBB3* comprises of extracellular ligand-binding domains (I--IV), a tyrosine kinase domain, and a regulatory domain ([@B52]). In concordance with previous studies, the majority of mutations detected in our patients are located in the extracellular domain (L143M, P558S, E560fs) of the gene which are predicted to induce conformational changes, dysregulate ligand binding, or heterodimerization of *ERBB3* with kinase-active *ERBB2* ([@B32]). Distinct from other EGFR members, *ERBB3* has impaired tyrosine kinase activity; hence, it could be hypothesized that mutations mapped on this domain (L924V) could activate and stimulate protein tyrosine kinase ([@B33]). These oncogenic mutations might promote tumorigenesis through aberrant activation of PI3K/AKT pathway, eliciting various biological responses including cell cycle progression, stimulation of cell migration, and invasion ([@B57]).

Perhaps the most promising gene from our study, based on mutation frequency and function, is WHSC1. It was more frequently mutated in the ER positive subtype. The WHSC1 gene encodes a histone methyltransferase, is classified as chromatin modification group, and plays an important role in regulating gene transcription ([@B42]). A previous study showed that *WHSC1* interacts with and regulate gene transcription activity of androgen receptors in prostate cancer ([@B36]) and ER in breast cancer ([@B18]), which provide a new basis for tumorigenesis in endocrine-related cancers. Hence, there is high possibility that *WHSC1* is involved in development of endometrial cancer. *WHSC1* is shown to be essential for ERα-dependent transcription induction in tamoxifen-resistant breast cancers, one of the potent coactivators in the ER pathway ([@B18]). They postulated that *WHSC1* is recruited to the ER promoter by the bromodomain protein (BRD4) and direct H3K36 methylation that is responsible for promoting transcription initiation and elongation. Moreover, genetic alterations in the transcriptional coregulators of ER genes are likely to be the key players in the development of estrogen-dependent tumors through deregulation in the estrogen signaling pathway ([@B25]), further supporting our hypothesis for *WHSC1* as the likely target gene in endometrial cancer.

*WHSC1* (MMSET/NSD2) spans 120 kb, consists of 24 exons that encode a 1360 amino acid protein containing catalytic SET domain, and several chromatin-associated domains comprising a high mobility group (HMG) box which often representing a DNA-binding domain, two PWWP domains, five PHD zinc fingers defined as binding modules for methylated lysines, and C5HCH domain (Cys--His-Rich). Previous studies have almost exclusively focused on translocation and overexpression of *WHSC1* while mutations in this gene have not yet been extensively characterized ([@B31]), even though the occurrence in a variety of cancers is increasingly reported ([@B30]; [@B23]). Based on our analysis, *WHSC1* is frequently mutated in the ER positive subtype where four mutations (K574E, R1126H, R824X, and L1268P) were identified in three patients. We went on to study the role of these mutations in cell transformation by performing transient transfection in EEC-1 cell lines (endometrial cancer cell line expressing ER), followed by luciferase-based assay. Of the four mutations, we observed that only two *WHSC1* mutations (R1126H and L1268P) resulted in increased cell proliferation, increased ability of the cells to migrate, and survive in clonogenic growth which represents gain of function phenotype. Both mutants are likely to exhibit increased level of methyltransferase activity of H3K36, which is generally thought to drive tumorigenesis, through activation of key genes ([@B56]). We postulate that the mutant R1126H which is located in the histone binding groove on SET domain, which is in proximity to the established hotspot mutants E1099K and D1125N, lead to a hyperactive *WHSC1*, causing an increase in methyltransferases activity and hence progression of malignancies ([@B31]). Since the mutant R1126H exhibited independent ER pathway activation, it may be involved in endometrial carcinogenesis through other pathways. Endometrial cancer may also be triggered through the transcriptional regulation of CCND1, the target gene of the β-catenin/Tcf-4 complex, through H3K36 methylation and activation of the WNT signaling pathway ([@B64]). This was supported by the discovery of recurrent R1126H mutants in colorectal cancer (**Supplementary Table [S10](#SM12){ref-type="supplementary-material"}**), where WNT signaling is the hallmark among the many genetic events. The other pathway that this mutation might be involved in is the RAS pathway by altering the oncogenic RAS transcriptional responses resulting in increased methyltransferase activity ([@B23]). However, there is still the need to elucidate which one is the key event since epigenetic alterations usually mediate the transcription of a plethora of genes ([@B29]).

Hormonal therapy and chemotherapy are frequently used for advanced endometrial cancer, and there is no approved molecular targeted therapy so far ([@B60]). However, in one clinical trial, the use of Fulvestrant has resulted in positive response in some patients with advanced or recurrent endometrial cancer ([@B16]). Fulvestrant is a selective ER downregulator (SERD) which competitively inhibits the binding of estradiol to the ER and it degrades ER via the ubiquitin-proteasome ([@B6]). Our study also provides evidence that Fulvestrant has the ability to induce ER degradation and that it inhibits the proliferation of the transforming mutant L1268P cells, which is associated with increased sensitivity to this treatment. Hence, we propose that Fulvestrant the potential to inhibit the activity of ER signaling pathway in this particular mutant.

Conclusion
==========

Using NGS, we have characterized the mutational landscape of different ER subtypes of EEC. We further demonstrated the role of the *WHSC1* L1268P mutation in endometrial cancer carcinogenesis by activating the ER signaling pathway and its pivotal role in promoting cell proliferation, migration, and survival. The ER signaling pathway activation by *WHSC1* LP1268H provides new evidence which is important for the future applications of targeted therapies for endometrial cancer carrying the WHSC1 L1268P mutations. A major limitation of our study is the small sample size, therefore further studies are warranted to explore the diagnostic and therapeutic potential of our discovery.
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